🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12467 total CTIS records — a stated recency window, not the full historical archive. Synced 22 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,467
Total on CTIS
full historical archive
744
Phase III
within the shown window
Top member states
Spain 1018 France 887 Germany 856 Italy 735 Poland 580 Netherlands 527
Narrow the register
Phase
Phase I 557 Phase I/II 211 Phase II 727 Phase III 744 Phase IV 261
Lead sponsor
AstraZeneca AB 62 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 47 Pfizer Inc. 44 Novo Nordisk A/S 43
Member state
Spain 1018 France 887 Germany 856 Italy 735 Poland 580 Netherlands 527 Belgium 424 Czechia 329
All 28 states
2500 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase III
Impact on delirium of the use of DEXmedetomidine as first-line sedation in PEDIAtric intensive care: the PEDIADEX randomized controlled trial
2025-521039-35-00Impact on delirium of the use of DEXmedetomidine as first-…
Centre Hospitalier Regional Universitaire De Tours
Anesthesia and Analgesia
France
29/10/2025
Phase II
DEPECA-1 – DEfeating PEnile CAncer 1 – A Phase II study to evaluate a first-line systemic therapy with enfortumab vedotin plus avelumab for advanced and metastatic penile carcinoma
2025-521644-37-00locally advanced or metastatic penile squamous cell carcino…
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Neoplasms
Germany
29/10/2025
Phase III
A multicenter, double-blind, placebo-controlled, clinical trial to evaluate the efficacy and safety of two concentrations of a mixture of depigmented polymerized allergenic extracts of D. pteronyssinus and D. farinae, in patients suffering from allergic rhinoconjunctivitis with or without controlled asthma
2025-521230-29-00Allergic rhinoconjunctivitis to Dermatophagoides pteronyssi…
LETI Pharma S.L.U.
Immune System Diseases
Spain, Portugal
29/10/2025
Phase III
Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity and type 2 diabetes
2024-519531-41-00Overweight and obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Czechia, Romania, Croatia, Slovakia, Hungary
29/10/2025
Phase II
A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults with Lewy Body Dementia Psychosis (LBDP)
2025-521710-25-00Lewy Body Dementia Psychosis (LBDP)
Acadia Pharmaceuticals Inc.
Nervous System Diseases
Bulgaria, Czechia, Italy, France
29/10/2025
Phase II
The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients
2025-521144-38-00Primary Central Nervous System Lymphoma
Bristol-Myers Squibb Services Unlimited Company
Nervous System Diseases
France, Germany
29/10/2025
Phase II
NEOREM/NEO-1 - NEOREM : Neo-adjuvant Adaptive Master Trial for Localized Cancers with Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology / NEO-1 : Neo-adjuvant intratumoral Anti-CTLA4 + Anti-PD1 treatment in patients with localized melanoma
2025-522127-95-00NEOREM: Localized solid malignancies that are eligible to r…
Unicancer
Neoplasms
France
28/10/2025
Phase III
Intralymphatic Allergen Immunotherapy (ILIT) in grass pollen allergy: a randomized controlled trial
2025-522376-82-00allergic diseases (allergic rhinosinusitis, allergic asthma…
University Of Foggia
Immune System Phenomena
Italy
28/10/2025
Phase II
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN2030 in Adult Patients with Antibody-Mediated Rejection after Kidney Transplantation
2024-517498-25-00Antibody-Mediated Rejection after Kidney Transplantation
Alexion Pharmaceuticals Inc.
Pathological Conditions, Signs and Symptoms
Spain
28/10/2025
Phase II
An open-label phase II trial to evaluate the clinical efficacy, safety and tolerability of MAS825 in pediatric and adult participants with Still’s disease
2024-520208-25-00Still’s disease
Novartis Pharma AG
Immune System Diseases
Italy, Netherlands, Spain, France, Germany
28/10/2025
Phase III
Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI-SAVE
2024-514693-47-01EGFR mutated locally advanced or metastatic non-small cell …
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Neoplasms
Netherlands, Belgium
28/10/2025
Phase III
Withdrawal of neurohormonal therapy in patients with non-ischemic cardiomyopathy, no late gadolinium enhancement, and negative genetic testing, who have exhibited super-response to cardiac resynchronization therapy. DRUGLESS-CRT clinical trial.
2025-521780-12-00Non-ischemic cardiomyopathy
Andrea Di Marco
Cardiovascular Diseases
Spain
28/10/2025
Phase I
European, multicentre, single arm (phase I) trial of autologous skeletal muscle derived cell (ASMDC) microcarrier combination for the treatment of faecal incontinence (FI) in women with obstetric anal sphincter injury.
2023-504282-23-00Faecal incontinence
University College London
Female Urogenital Diseases and Pregnancy Complications
France, Spain, Austria, Denmark
28/10/2025
Phase I
AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors
2025-521707-48-00KRAS Altered Advanced or Metastatic Solid Tumors
Amgen Inc.
Neoplasms
France, Netherlands, Germany, Denmark, Spain, Italy, Belgium
28/10/2025
Phase IV
PROlonged versus Single dose in PEnicillin oral Challenge Testing double-blind parallel randomized placebo cOntrolled tRial – PROSPECTOR-2 Study
2025-520888-41-00Penicillin allergy
Gentofte Hospital, Austin Health
Immune System Diseases
Belgium, Denmark
28/10/2025
Phase II
A Phase 2b, Multi-center, Randomized, Double-blind, Placebo controlled Study of IMVT-1402 Treatment in Adult Participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2024-517614-14-00Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Immunovant Sciences GmbH
Immune System Diseases
Austria, Hungary, Slovenia, Greece, Denmark, Ireland, Finland, Estonia, Spain, Slovakia, Netherlands, Poland, Norway, Italy, Portugal, Belgium, Germany, Romania, Bulgaria
28/10/2025
Phase III
Bisoprolol for pericarditis -Phase III randomized controlled clinical trial in patients with acute or recurrent pericarditis
2025-523015-11-00Pericarditis
Azienda Sanitaria Universitaria Friuli Centrale
Cardiovascular Diseases
Italy
27/10/2025
Phase II
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
2024-519820-26-00Hallucinations and Delusions Associated with Alzheimer’s Di…
Maplight Therapeutics Inc.
Nervous System Diseases
France, Czechia, Slovakia, Hungary, Portugal, Romania, Bulgaria, Italy, Poland
27/10/2025
Phase IV
A Phase IV, open label, single arm trial to assess the safety and immunogenicity of BIMERVAX® LP.8.1 against SARS-CoV-2 variants.
2025-524021-41-00COVID-19
Hipra Scientific S.L.
Virus Diseases
Spain
27/10/2025
Phase II
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Rheumatoid Arthritis
2025-521745-25-00Rheumatoid Arthritis
Merck Sharp & Dohme LLC
Immune System Diseases
Poland, Spain, Germany
27/10/2025
Phase III
A Phase III, randomized, multi-site, open-label trial of BNT323/DB-1303 versus investigator’s choice of chemotherapy in previously treated patients with HER2- expressing recurrent endometrial cancer
2023-507525-42-00Endometrial cancer
BioNTech SE
Female Urogenital Diseases and Pregnancy Complications
Denmark, Poland, Italy, Finland, Czechia, Sweden, Greece, Belgium, Norway, Hungary, Germany, Austria, France, Spain, Netherlands
27/10/2025
Phase III
A Phase 3, Multi-Site, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of eRapa to Improve Clinical Outcomes in Participants with Familial Adenomatous Polyposis
2025-522946-37-00Familial adenomatous polyposis (FAP)
Biodexa Limited, Rapamycin Holdings Inc.
Virus Diseases
Denmark, Spain, Germany, Netherlands, Italy
27/10/2025
Phase I
A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Bupropion Hydrochloride Sustained-Release Tablets 150 mg, manufactured for Sun Pharmaceutical Industries Limited, India with PrOdan Bupropion SR (Bupropion Hydrochloride Sustained-Release Tablets 150 mg), product of Odan Laboratories Ltd., 325 Stillview Avenue, Pointe Claire, Quebec, H9R 2Y6, in healthy adult, human subjects under fasting condition.
2024-516034-35-00major depressive illness
Sun Pharmaceutical Industries Limited
Mental Disorders
Romania
27/10/2025
Phase I
A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Bupropion Hydrochloride Sustained-Release Tablets 150 mg, manufactured for Sun Pharmaceutical Industries Limited, India with PrOdan Bupropion SR (Bupropion Hydrochloride Sustained-Release Tablets 150 mg), product of Odan Laboratories Ltd., 325 Stillview Avenue, Pointe Claire, Quebec, H9R 2Y6, in healthy adult, human subjects under fed condition.
2024-516035-27-00major depressive illness
Sun Pharmaceutical Industries Limited
Mental Disorders
Romania
27/10/2025
Phase I
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTIPLE RISING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF DEURUXOLITINIB IN HEALTHY ADULTS
2025-522097-36-00alopecia areata
Sun Pharmaceutical Industries Inc.
Immune System Diseases
Romania
27/10/2025
Phase I
A Study Testing the Investigational Drug XmAb541 in people with Advanced Cancer
2025-521981-90-00Advanced Solid Tumors
Xencor Inc.
Neoplasms
Spain, France, Belgium, Denmark
27/10/2025
Phase I
Research into the safety of a new agent (AX-5006) in people with and without Parkinson's disease.
2025-523254-14-00Parkinson's disease
Vertero Therapeutics Inc.
Nervous System Diseases
Netherlands
27/10/2025
Phase I/II
A single-arm, multicenter, open-label, Phase I/II trial of Allo-QuadCAR01-T, an allogeneic CAR-T-cell therapy targeting CD19 and CD20, for the treatment of relapsed or refractory B-cell malignancies
2025-521735-36-00Relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL)…
Avencell Therapeutics Inc.
Neoplasms
Germany
27/10/2025
Phase IV
Long-term muscle synthetic effects of intradialytic parenteral nutrition in chronic hemodialysis patients
2025-522111-42-02muscle protein turnover hemodialysis
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Nutritional and Metabolic Diseases
Netherlands
27/10/2025
Phase I
Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi®, and US licensed Skyrizi® in Healthy Adult Participants
2025-522345-21-00Moderately to severely active Crohn’s disease, Moderately t…
Chong Kun Dang Pharmaceutical Corp.
Immune System Diseases
Poland
26/10/2025
Phase III
68Ga-FAPI PET/CT imaging to assess pulmonary artery and right ventricle remodeling SoFAPI study
2025-520731-17-02Pulmonary arterial hypertension (PAH)
Centre Hospitalier Regional Et Universitaire De Brest
Diagnosis
France
24/10/2025
Phase II
BASECOVID - Bevacizumab in post-acute sequelae of COVID-19 : Efficacy and Safety (Pilot Study)
2024-520308-24-00Adult patients with persistent dyspnea more than 3 months a…
Assistance Publique Hopitaux De Paris
Virus Diseases
France
24/10/2025
Phase II
CAT-VHL - Exploring the role of Carbonic Anhydrase IX as diagnostic and Theranostic target in Von-Hippel Lindau disease
2024-515679-36-01Von-Hippel Lindau (VHL) Disease
Ospedale San Raffaele S.r.l.
Therapeutics
Italy
24/10/2025
Phase II
Randomized Multicentric Proof-of-Concept Phase 2 Trial Doravirine in the Early Outpatient Management of West Nile Virus Infection in Patients at Risk of Progression - DORICO Trial
2025-521677-14-00West Nile Virus Infection
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Virus Diseases
Italy
24/10/2025
Phase II
Cityview: PET-Based Imaging to Evaluate the Distribution of Radiolabeled CIT-013 in Patients with Inflammatory Mediated Immune Disease
2025-522189-60-00Inflammatory mediated immune diseases
Citryll B.V.
Immune System Diseases
Netherlands
24/10/2025
Phase I
A research study of a new medicine, NNC9733-0001, in healthy participants and participants with type 2 diabetes
2024-519382-22-00Healthy Participants and Participants with type 2 diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Germany
24/10/2025
Phase III
A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination with Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants with Homozygous MTAP Deletion.
2025-521511-40-00metastatic non-small cell lung cancer
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Greece, Czechia, France, Sweden, Romania, Belgium, Austria, Bulgaria, Italy, Netherlands, Denmark, Germany, Poland, Hungary, Spain
24/10/2025
Phase IV
Effect of Semaglutide on embryo quality in overweight and obese patients undergoing In Vitro Fertilization. A Randomized Controlled Trial
2025-522525-34-00Infertility
Santiago Dexeus Font Fundacio Privada
Female Urogenital Diseases and Pregnancy Complications
Spain
24/10/2025
Phase III
A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease
2025-521398-15-00Immune system diseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Netherlands, Spain, France, Belgium, Sweden, Germany, Poland, Italy
24/10/2025
Phase II
LUSPARA - A basket phase II clinical trial evaluating Luspatercept in patients affected with rare inherited anemias
2024-520200-26-00Inherited anemias
Eurobloodnet Association
Hemic and Lymphatic Diseases
Italy, France
24/10/2025
Phase II
ALTER : A Phase 2, Multicenter, Randomized, Open-label trial assessing sacituzumab-govitecan and trastuzumab-deruxtecan combinaison in an ALTERnating regimen for patients with metastatic or locally advanced Her2-low triple-negative breast Cancer
2025-521909-40-00Patients with metastatic or locally advanced HER2-low tripl…
Unicancer
Neoplasms
France
23/10/2025
Phase II
Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor
2025-520468-16-00Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced U…
Genmab A/S
Neoplasms
France, Spain, Netherlands, Germany
23/10/2025
Phase II
Local tenecteplase applicatiOn subsequent to endovasCular recanalization in Anterior circuLation stroke - the LOCAL trial
2024-516544-26-00acute ischemic stroke
Universitaetsklinikum Heidelberg AöR
Cardiovascular Diseases
Germany
23/10/2025
Phase III
A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Dotinurad Compared With Allopurinol in Adult Participants With Hyperuricemia Associated With Gout
2024-520206-19-00Hyperuricemia associated with gout.
Crystalys Therapeutics Inc.
Musculoskeletal Diseases
Spain, Poland
23/10/2025
Phase II
An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negative metastatic triple-negative breast cancer
2024-519913-76-00PDL1-negative metastatic triple-negative breast cancer
Queen Mary University Of London
Neoplasms
Spain, Germany
23/10/2025
Phase III
RANDOMISED, MULTICENTRE, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MONTELUKAST VS. PLACEBO IN PATIENTS WITH EROSIVE/INFLAMMATORY OSTEOARTHRITIS OF THE HANDS. MOTHER Study.
2025-521802-17-00Erosive/inflammatory osteoarthritis of the hands
Farmalider S.A.
Musculoskeletal Diseases
Spain, Italy, Portugal
23/10/2025
Phase II
A Multi-Center, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 [AL101] in Participants with Early Alzheimer’s Disease.
2025-521107-42-00Alzheimer's Disease
Glaxosmithkline Research & Development Limited
Nervous System Diseases
Sweden, Norway, Italy, France, Spain, Finland, Netherlands, Germany
23/10/2025
Phase II
Preoperative use of Romiplostim in thrombocytopenic patients undergoing cardiac surgery. A Phase 3, multicenter randomized double-blinded controlled against placebo study
2024-517710-15-00thrombocytopenic patients undergoing cardiac surgery
Centre Hospitalier Universitaire De Nantes
Surgical Procedures, Operative
France
22/10/2025
Phase III
A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)
2024-513676-18-00Transthyretin Amyloidosis
Eidos Therapeutics Inc.
Cardiovascular Diseases
Germany, Portugal, Netherlands, France, Spain, Italy, Ireland, Belgium, Sweden, Denmark, Greece
22/10/2025
Phase IV
The Role of Beta-Blockade During Cardiac CT in Patients with Atrial Fibrillation
2025-523391-22-01Atrial fibrillation, Coronary artery disease
Semmelweis University
Cardiovascular Diseases
Hungary
22/10/2025
Phase IV
F-puff_SE_2024
2024-519131-42-02PAIN MANAGEMENT
Semmelweis University
Not possible to specify
Hungary
22/10/2025
Phase II
A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants with Advanced Prostate Cancer
2024-517653-27-00Prostate Cancer
Astellas Pharma Global Development Inc.
Neoplasms
Italy, Poland, Spain, France, Germany
22/10/2025
Phase I
Phase 1 Study to Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Men Participants
2025-521402-18-00Desmoid tumor
Springworks Therapeutics Inc.
Skin and Connective Tissue Diseases
Netherlands
22/10/2025
Phase III
Pre- and post-treatment evaluation of lung function with Xenon-gas enhanced Dual-Energy CT-imaging in patients undergoing radiotherapy
2025-521559-22-00Radiation-induced lung injury (radiation fibrosis, radiatio…
UZ Brussel
Diagnosis
Belgium
22/10/2025
Phase II
The HIt HArd and hiT early in multiple sclerosis trial – HiHat trial
2024-519700-28-01Patients with relapsing-remitting multiple sclerosis with l…
Region Uppsala
Nervous System Diseases
Sweden
22/10/2025
Phase III
STOP-HAE: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
2025-521352-38-00Hereditary Angioedema
Adarx Pharmaceuticals Inc.
Immune System Diseases
Belgium, Poland, Italy, Czechia, Hungary, Spain, Germany, Croatia, France, Bulgaria, Austria
22/10/2025
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-2)
2025-520612-34-00Agitation Associated with Alzheimer’s Disease
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Poland, Hungary, Italy, France, Czechia
22/10/2025
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia
2024-514401-54-00Chronic Primary Immune Thrombocytopenia
Takeda Development Center Americas Inc.
Hemic and Lymphatic Diseases
Poland, Spain, Bulgaria, Italy, Netherlands, Croatia, Germany, Sweden, Greece, Czechia, Norway, France
22/10/2025
Phase III
The "MAGNEFFICIENT" Prospective Trial: Preoperative Administration of MAGNesium for EFFICIENT Parathyroids after Thyroidectomy
2025-522839-33-00Postoperative Hypoparathyroidism after thyroid surgery.
Henry Dunant Hospital Center
Hormonal diseases
Greece
22/10/2025
Phase III
Prevention of RSV infection in infants by administering nirsevimab to infants, with or without maternal RSV vaccination: a randomised controlled trial in France as part of the Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)
2025-521755-23-00Respiratory syncytial virus infection, Bronchiolitis, Respi…
Centre Hospitalier Annecy Genevois
Health Care Economics and Organizations
France
21/10/2025
Phase III
A Single Arm Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria with Inadequate Control of Intravascular Hemolysis on Currently Available C5 Inhibitor Therapy
2024-519709-37-00Paroxysmal nocturnal hemoglobinuria (PNH)
Regeneron Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Poland, Italy, Spain
21/10/2025
Phase II
A Phase IIb Randomized, Double-blind, Placebo-controlled, Multi-Dose Study to Evaluate the Effects of PHENOGENE-1a (Cromolyn) as an Adjuvant Treatment in Subjects with Mild to Moderate Amyotrophic Lateral Sclerosis (ALS)
2025-520688-42-00Amyotrophic Lateral Sclerosis (ALS)
Phenonet Inc.
Nervous System Diseases
Germany, Czechia, Poland, Spain
21/10/2025
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease (MINDSET 1)
2025-520746-30-00Mild to moderate Alzheimer’s Disease
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Germany, Croatia, Italy, Poland, Romania, Czechia, Greece, Spain, Netherlands
21/10/2025
Phase II
A Phase II Open-Label Pilot Trial Assessing the Safety of Anifrolumab in Adult Patients with Primary Antiphospholipid Syndrome (APS). The AnifAPS trial.
2025-520918-64-00Primary Antiphospholipid Syndrome (APS)
National And Kapodistrian University Of Athens
Immune System Diseases
Greece
21/10/2025
Phase II
A Phase 2, Multicenter, Randomized, Double blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants with Colorectal Cancer who have Cancer Cachexia (SAPPHIRE)
2025-521730-28-00Colorectal Cancer with Cancer Cachexia
Ngm Biopharmaceuticals Inc.
Nutritional and Metabolic Diseases
Czechia, Slovakia, Poland, Hungary, Bulgaria
21/10/2025
Phase III
CN012-0025: A Phase 3, Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-3)
2024-519994-20-00Agitation Associated with Alzheimer’s Disease
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Croatia, Romania, France, Spain, Italy, Greece, Czechia, Bulgaria, Poland, Portugal, Hungary
21/10/2025
Phase II
A Phase 2, Double-Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Apitegromab in Subjects <2 Years Old With Spinal Muscular Atrophy (SMA) (OPAL)
2024-520130-29-00Spinal Muscular Atrophy
Scholar Rock Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Belgium, France, Italy, Spain, Netherlands
21/10/2025
Phase I/II
A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination with Elranatamab in Participants with Relapsed and/or Refractory Multiple Myeloma
2025-522090-11-00Relapsed or Refractory Multiple Myeloma (RRMM)
Celgene Corp.
Neoplasms
Norway, Greece, Germany, Spain
21/10/2025
Phase IV
ENDO-67 project: Investigating ENDOcrine therapy-related questions using Ki67 changes in the window-of-opportunity before breast surgery
2025-521385-10-00Breast cancer
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Neoplasms
Netherlands
21/10/2025
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild to Moderate Alzheimer’s Disease (MINDSET 2)
2025-520747-32-00Mild to moderate Alzheimer’s Disease
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Germany, Netherlands, Portugal, France, Spain, Poland, Greece, Romania, Italy, Finland
21/10/2025
Phase III
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF DIVARASIB AND PEMBROLIZUMAB VERSUS PEMBROLIZUMAB AND PEMETREXED AND CARBOPLATIN OR CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED, KRAS G12C-MUTATED, ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
2024-518365-10-00Previously Untreated Advanced or Metastatic Non-Squamous No…
F. Hoffmann-La Roche AG
Neoplasms
Ireland, Greece, Hungary, Netherlands, France, Denmark, Germany, Poland, Italy, Portugal, Spain, Belgium
21/10/2025
Phase II
Cangrelor in endovascular stroke treatment with emergent carotid artery stenting (CANCAS)
2025-521564-35-00ischemic stroke with intracranial large artery occlusion of…
Medical University Of Graz
Nervous System Diseases
Austria
20/10/2025
Phase IV
MetAddon: Methadone as co-analgesic for patients with metastatic bone pain: a double-blind randomized controlled trial
2025-522710-22-00Cancer, bone metastasis, pain
Universiteit Maastricht
Neoplasms
Netherlands
20/10/2025
Phase III
Pregabalin or Baclofen in Spastic Motor Behavior Treatment After SCI (PoBSCI), Prospective, Double-Blind, Randomised Drug Study
2024-518824-56-00Complete to incomplete (AIS A-C) sub-acute cervical or thor…
Fakultni Nemocnice V Motole
Musculoskeletal Diseases
Czechia
20/10/2025
Phase II
BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, multicenter, comparative, randomized GERCOR G-124 BETWEEN phase II study
2024-520128-27-00colorectal adenocarcinoma
Association Gercor
Digestive System Diseases
France
20/10/2025
Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children with Hypochondroplasia, Aged 0 to < 36 Months
2024-512261-14-00Hypochondroplasia
Biomarin Pharmaceutical Inc.
Genetic Phenomena
Germany, Italy, France
20/10/2025
Phase II
Phase II randomized trial of XELOX plus DoSTARlimab versus XELOX alone as Consolidation Treatment after Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients – IMMUNOSTAR Trial  -  GOIRC-02-2024
2024-519798-20-00pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC)
G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica
Neoplasms
Italy
20/10/2025
Phase III
A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 µg in 1-through 3-year-old Children with Peanut Allergy
2025-521697-34-00Peanut allergy
Dbv Technologies
Immune System Diseases
Spain, France, Netherlands, Ireland
20/10/2025
Phase III
RANDOMISED CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF PLATELET-RICH PLASMA (PRP) INFILTRATION COMBINED WITH PHYSICAL EXERCISE IN CHRONIC OMALGIA
2025-522700-24-00CHRONIC OMALGIA
Asociacion Instituto De Investigacion Sanitaria Biobizkaia
Musculoskeletal Diseases
Spain
20/10/2025
Phase II
PRObiotic Therapy Examining Combinatorial Therapeutics in Multiple Sclerosis - phase II, multicenter, randomised, open-label clinical trial.
2025-520955-10-00Multiple sclerosis
Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
Nervous System Diseases
Poland
20/10/2025
Phase III
C4551002 - An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07248144 Plus Fulvestrant Compared to Investigator’s Choice of Therapy in Adult Participants with Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy
2025-520566-22-00Hormone Receptor-Positive, HER2-Negative Advanced/Metastati…
Pfizer Inc.
Neoplasms
Hungary, Bulgaria, Czechia, Slovakia, Netherlands, Spain, Greece, Finland, Belgium, Sweden, Poland, Germany, France, Italy
20/10/2025
Phase II
Blomia tropicalis allergen extract. Determination of the vivo histamine equivalent prick test units
2024-515169-33-00Allergy to Blomia tropicalis
Inmunotek S.L.
Immune System Diseases
Spain
20/10/2025
Phase II
A Phase 2, Multi-Center, Platform Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics with Multiple Therapies in Participants with Active Crohn’s Disease or Active Ulcerative Colitis (ASCEND-IBD)
2025-522001-38-00Crohn’s Disease, Ulcerative Colitis
Mirador Therapeutics Inc.
Digestive System Diseases
Poland, Bulgaria, Croatia, Germany, Belgium, Slovakia, Czechia, Italy
20/10/2025
Phase III
A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis
2024-515979-35-00Generalized Myasthenia Gravis
Immunovant Sciences GmbH
Nervous System Diseases
Czechia, Greece, Spain, Italy, Denmark, Germany, Romania, Poland, Hungary
20/10/2025
Phase III
The IMAGINE study: A phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with Type 2 inflammation characterized by an eosinophilic phenotype utilizing quantitative high-resolution CT and bronchoscopic airway sampling in a sub study
2024-519976-19-00Asthma with type 2 inflammation characterized by an eosinop…
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Belgium, Spain, Italy, Greece, France, Germany
20/10/2025
Phase II
EPIK-P4: A Phase II single arm study to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)
2024-519960-42-00PIK3CA-Related Overgrowth Spectrum (PROS)
Novartis Pharma AG
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Italy, Netherlands, Belgium, Spain, Austria, Germany, France
20/10/2025
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated with Alzheimer’s Disease (ADAGIO-1)
2025-520613-31-00Agitation Associated with Alzheimer’s Disease
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Portugal, Croatia, Bulgaria, Greece, Spain, Romania
20/10/2025
Phase II
EFfIcacy and Tolerability of FIXed duration teclistamab and talquetamab FOR FRAIL patients with newly diagnosed multiple myeloma (2 cohort study) - the EMN 37 FITFIX FOR FRAIL trial
2024-520433-76-00Newly Diagnosed Multiple Myeloma
European Myeloma Network B.V., Emn Trial Office S.r.l. Impresa Sociale
Neoplasms
Norway, Italy, Spain, Netherlands
20/10/2025
Phase II
RENAISSANCE 2: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures
2025-520587-18-00Focal Onset Seizures
Supernus Pharmaceuticals Inc.
Nervous System Diseases
Poland, Hungary, Bulgaria
20/10/2025
Phase II
PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.
2024-519753-11-00Resectable borderline pancreatic adenocarcinoma
Fondation Franc.Cancerologie Digestive
Digestive System Diseases
France
17/10/2025
Phase III
IZABRIGHT-Breast01: A Randomized, Open-label, Inferentially Seamless Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer (TNBC) or ER-low, HER2-negative BC who are Ineligible for Anti-PD1/PD-L1 Treatment
2024-519871-24-00Breast cancer, Triple-negative breast cancer
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
France, Portugal, Romania, Greece, Italy, Spain, Sweden, Austria, Poland, Germany
17/10/2025
Phase II
Efficacy of probenecid on cluster seizures during dosage reduction of Anti Seizure Medication (ASM) in presurgical focal epilepsy video-EEG monitoring
2024-519133-29-00Focal epilepsy
Fondation A De Rothschild
Nervous System Diseases
France
17/10/2025
Phase I/II
A Phase I/II, open-label, adaptive two-part trial to evaluate the safety, efficacy, optimal dose and pharmacokinetics of BNT326 as monotherapy and in combination with cancer immunotherapies in participants with advanced solid tumors
2024-517261-16-00Advanced solid tumors
BioNTech SE
Neoplasms
Belgium, Germany, Spain, Italy
17/10/2025
Phase II
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
2025-521920-31-00Graves’ Disease
Immunovant Sciences GmbH
Immune System Diseases
Italy, Poland, Greece, Germany, Netherlands, Czechia, Spain, Latvia, Bulgaria
17/10/2025
Phase I
Food effect and single- and multiple-ascending dose clinical trial of DF2755A in healthy participants
2025-522935-32-00interstitial cystitis/bladder pain syndrome
Dompe' Farmaceutici S.p.A.
Pathological Conditions, Signs and Symptoms
Netherlands
17/10/2025
Phase II
A Phase 2, Randomized, Open-Label Study Of Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)
2025-521849-25-00Chronic Graft-Versus-Host Disease
Incyte Corp.
Immune System Diseases
Spain, Belgium, Germany, Italy
17/10/2025
Phase I
A Study of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment
2025-521947-19-00Healthy, Hepatic Insufficiency
Eli Lilly & Co.
Digestive System Diseases
Slovakia, Hungary
17/10/2025
Phase III
Immunomodulatory therapy to restore ovarian function and improve fertility in women with autoimmune premature ovarian insufficiency – a double-blind, placebo-controlled, randomized study
2025-522133-66-00Autoimmune Premature Ovarian Insufficiency
Karolinska University Hospital
Female Urogenital Diseases and Pregnancy Complications
Sweden
17/10/2025
Phase III
EUROpean pragmatic multicenter randomized trial on platelet inhibition and/or lipid lowering treatment in Covert Brain Infarction (CBI)
2025-521452-30-01Covert brain infarction (asymptomatic brain infarctions)
Region Midtjylland
Nervous System Diseases
Denmark, Sweden, Norway
17/10/2025
Phase III
Low dose corticosteroids adjacent to enzyme replacement therapy or chaperon therapy in patients with cardiac manifestation of Fabry disease – prospective randomized controlled phase III trial
2025-521408-24-00Fabry disease
Medical University Of Lodz
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Poland
17/10/2025
Rows per page Showing 2101–2200 of 2500
Previous 20 21 22 23 24 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS). Derived from the EMA Clinical Trials Information System. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-europe?page=22

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.